Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: Correlation with proliferation

Human Pathology

Volumn 33, Issue 9, 2002, Pages 863-870

  Nakopoulou, Lydia ^a   Stefanaki, Kalliopi ^a   Panayotopoulou, Effie ^a   Giannopoulou, Ioanna ^a   Athanassiadou, Pauline ^a   Gakiopoulou Givalou, Hariklia ^a   Louvrou, Androniki ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer; Fetal liver kinase (Flk 1) KDR; Proliferation

Indexed keywords

AVIDIN; BIOTIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ESTROGEN RECEPTOR; FETAL LIVER KINASE 1; KI 67 ANTIGEN; MESSENGER RNA; ONCOPROTEIN; PEROXIDASE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MENOPAUSE; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL;

EID: 0036740955     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2002.126879     Document Type: Article

References (58)

1. Plate KH, Breier G, Risau W: Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 4:207-218, 1994
2. Feige JJ, Bailly S: Molecular bases of angiogenesis. Bull Acad Natl Med 184:537-544, 2000
3. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996
4. Klagsbrun M, D'Amore PA: Regulators of angiogenesis. Ann Rev Physiol 53:217-239, 1991
5. Neufeld G, Cohen T, Gengrinovitch S, et al: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22, 1999
6. Frelin C, Ladoux A, D'Angelo G: Vascular endothelial growth factors and angiogenesis. Ann Endocrinol (Paris) 61:70-74, 2000
7. McMahon G: VEGF receptor signaling in tumor angiogenesis. Oncologist 5(Suppl 1):3-10, 2000
8. Breier G, Clauss M, Risau W: Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 204:228-239, 1995
9. Tomanek RJ, Ratajska A, Kitten GT, et al: Vascular endothelial growth factor expression coincides with coronary vasculogenesis and angiogenesis [in process citation]. Dev Dyn 215:54-61, 1999
10. Gerber HP, Hillan KJ, Ryan AM, et al: VEGF is required for growth and survival in neonatal mice. Development 126:1149-1159, 1999
11. Carmeliet P, Collen D: Transgenic mouse models in angiogenesis and cardiovascular disease. J Pathol 190:387-405, 2000
12. DeVries C, Escobedo JA, Ueno H, et al: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991, 1992
13. Millauer B, Wizigmann-Voos S, Schuurch H, et al: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846, 1993
14. Ferrara N, Carver-Moore K, Chen H, et al: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442, 1996
15. Shalaby F, Rossant J, Yamaguchi TP, et al: Failure of blood island formation and vasculogenesis in Flk-1 deficient mice. Nature 376:62-66, 1995
16. Dvorak H, Nagy JA, Feng D, et al: Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237:97-132, 1997
17. O'Brien T, Cranston D, Fuggle S, et al: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 55:510-513, 1992
18. Ellis LM, Staley CA, Liu W, et al: Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for src. J Biol Chem 273:1052-1057, 1998
19. Brown LF, Berse B, Jackman RW, et al: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53:4727-4735, 1993
20. Takahashi A, Sasaki H, Jinkim S, et al: Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem Biophys Res Commun 257:855-859, 1999
21. Millauer B, Shawer LK, Plate KH, et al: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579, 1994
22. Davidoff AM, Leary MA, Ng CY, et al: Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor Flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 36:30-36, 2001
23. Brown LF, Berse B, Jackman RW, et al: Expression of vascular permeability factor (vascular endothelial factor) and its receptors in breast cancer. Hum Pathol 55:510-513, 1995
24. Yoshiji H, Gomez DE, Shibuya M, et al: Expression of vascular endothelial growth factor, its receptors and other angiogenic factors in human breast cancer. Cancer Res 56:2013-2016, 1996
25. De Jong JS, van Diest PJ, Van der Valk P, et al: Expression of growth factors, growth inhibiting factors and their receptors in invasive breast cancer I: An inventory in search of autocrine and paracrine loops. J Pathol 184:44-52, 1998
26. Gomez DE, Alonso DF, Yoshiji H, et al: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 74:111-112, 1997
27. Fata JE, Leco KJ, Moorehead RA, et al: Timp-1 is important for epithelial proliferation and branching morphogenesis during mouse mammary development. Devel Biol 211:238-254, 1999.
28. Khokha R: Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of metalloproteinases-1. J Natl Cancer Inst 86:299-304, 1994
29. Takigawa M, Nishida Y, Suzuki F, et al: Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2). Biochem Biophys Res Commun 171:1264-1271, 1990
30. Guedez L, McMarlin AJ, Kingma DW, et al: Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 158:1207-1215, 2001
31. Association of Directors of Anatomic and Surgical Pathology Recommendations for life reporting of breast carcinoma. Hum Pathol 27:220-224, 1996
32. Hsu SM, Raine L, Fanger H: The use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique. A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580, 1981
33. McClelland RA, Wilson D, Leake R: A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer 27:711-716, 1991
34. Nakopoulou L, Giannopoulou I, Stefanaki K, et al: Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinoma is correlated with adverse prognosis. J Pathol 197:307-313, 2002
35. Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H, et al: Markers of tumor angiogenesis and proteolysis independently define high and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16:3129-3136, 1998
36. Nakopoulou L, Lekkas N, Lazaris AC, et al: An immunohistochemical analysis of angiogenesis in invasive breast cancer with correlations to clinicopathologic predictors. Anticancer Res 19:4547-4554, 1999
37. Nakopoulou L, Lazaris AC, Kavantzas N, et al: DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 68:137-143, 2000
38. Gitay-Goren H, Halaban R, Neufeld G: Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 190:702-708, 1993
39. Boocock CA, Charnock-Jones S, Sharkey AM, et al: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 7:506-516, 1995
40. Shibaya M: Role of VEGF-Flt receptor in normal and tumor angiogenesis. Adv Cancer Res 67:281-316, 1995
41. Barleon B, Sozzani S, Zhou D, et al: Migration of human monocytes in response to vascular endothelial growth factor is mediated via the VEGF receptor flt-1. Blood 87:3336-3343, 1996
42. Yang K, Cepko CL: Flk-1, a receptor for vascular endothelial growth factor (VEGF) is expressed in retinal progenitor cells. J Neurosci 16:6089-6099, 1996
43. Enomoto T, Okamoto T, Sato JD: Vascular endothelial growth factor induces the disorganization of actin stress fibers accompanied by protein phosphorylation and morphological change in Ba1b/C3T3 cells. Biochem Biophys Res Commun 202:1716-1723, 1994
44. Von Marschall Z, Cramer T, Hocker M, et al: Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48:87-96, 2001
45. Von Marschall Z, Cramer T, Hocker M, et al: De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop. Gastroenterology 119:1358-1372, 2000
46. Mascood R, Cai J, Zheng T, et al: Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci U S A 94:979-984, 1997
47. Xie B, Tam NNC, Tsao SW, et al: Coexpression of vascular endothelial growth factor (VEGF) and its receptors (Flk-1 and flt-1) in hormone induced mammary cancer in the Noble rat. Br J Cancer 81:1335-1343, 1999
48. Roberts GW, Delaat J, Nagane M, et al: Host microvasculature influence on tumor vascular morphology and endothelial gene experssion. Am J Pathol 153:1239-1248, 1998
49. D'Angelo G, Struman I, Martial J, et al: Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the anti-angiogenic factor 16 kDA-N-terminal fragment of prolactin. Proc Natl Acad Sci U S A 92:6374-6378, 1995
50. Waltenberger J, Claessou-Welsh L, Siegbahn A, et al: Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995, 1994
51. Prewett M, Huber J, Li Y, et al: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209-5218, 1999
52. Shaheen RM, Tseng WW, Vellagas R, et al: Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity and apoptosis in a murine model of colon carcinomatosis. Int J Oncol 18:221-226, 2001
53. Ali SH, O'Donell AL, Balu D, et al: Estrogen receptor alpha in the inhibition of cancer growth and angiogenesis. Cancer Res 60:7094-7098, 2000
54. Bausero P, Ben-Mahdi M, Mazucafelli J, et al: Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen and hypoxia. Am J Physiol Heart Circ Physiol 279:H2033-H2042, 2000
55. Hyder SM, Murthy L, Stancel GM: Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 58:392-395, 1998
56. Classen-Linke I, Alfer J, Krusche CA, et al: Progestins, progesterone receptor modulators and progesterone antagonists change VEGF release of endothelial cells in culture. Steroids 65:763-771, 2000
57. Linderholm B, Tavelin B, Grankvist K, et al: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16:3121-3128, 1998
58. Johnson MD, Kim HC, Chesler L, et al: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160: 194-202, 1994